Citations

Showing 10 of 108094 citations.

Old age amyotrophic lateral sclerosis and limbic TDP‐43 pathology
Nakamura, M. , Koga, Shunsuke , Sekiya, Hiroaki , Oskarsson, Björn , Petrucelli, Leonard , Josephs, Keith A. , Dickson, Dennis W. , Nakamura, M , Boylan, Kevin, Josephs, Keith A , Dickson, Dennis W , Koga, Shunsuke , Oskarsson, Björn , Sekiya, Hiroaki , Boylan, Khrista

Mayo Clinic

Brain Pathology | June 18, 2022 | Volume: 32 | Issue: 6 | Pages: No page available

10.1111/bpa.13100 | PMID 35715944 Get It

AbstractThis study aimed to assess and compare the burden of transactive response DNA‐binding protein of 43 kDa (TDP‐43) pathology and clinical features of amyotrophic lateral sclerosis (ALS) in three age groups. All cases were from the Mayo Clinic brain bank for neurodegenerative disorders and most were followed longitudinally in the ALS Clinic. Cases with moderate‐to‐severe Alzheimer's disease neuropathological change were excluded. The 55 cases included in the study were divided into three groups by age at death: 75 years or older (old‐ALS, n = 8), 64–74 years (middle‐ALS, n = 23), and 63 years or younger (young‐ALS, n = 24). Clinical features, including disease duration, initial symptoms, and ALS Cognitive Behavior Score (ALS‐CBS), were summarized. Sections of paraffin‐embedded tissue from the motor cortex, basal forebrain, medial temporal lobe, and middle frontal gyrus were processed for phospho‐TDP‐43 immunohistochemistry. The burden of TDP‐43 pathology was analyzed using digital image analysis. The TDP‐43 burden in the limbic system (i.e., amygdala, dentate gyrus and CA1 sector of the hippocampus, subiculum, and entorhinal cortex) was greater in old‐ALS than in young‐ALS and middle‐ALS. TDP‐43 burden in the middle frontal gyrus was sparse and did not differ between the three groups. The average of ALS‐CBS was not different between the three groups. The present study shows that the amygdala and hippocampus are vulnerable to TDP‐43 pathology in older patients with ALS. We discuss the evidence for and against this pathology being related to concurrent limbic‐predominant, age‐related TDP‐43 encephalopathy neuropathologic change.
DNA methylation signature predicts cancer response to demethylation agents from profiling diverse cancer cell lines
Wang, Xuewei , Vedell, Pete, Kocher, Jean‐Pierre , Sun, Zhifu , Vedell, Peter T.

Mayo Clinic

Cancer Communications | June 18, 2022 | Volume: 42 | Issue: 8 | Pages: 789-792

10.1002/cac2.12326 | PMID 35716010 Get It

Occupational allergic contact dermatitis to sodium metabisulfite in shredded coconut
Hamann, Carsten R. , O’Hern, Keegan , Zug, Kathryn A. , O'Hern, Keegan , Baker, Catherine

Mayo Clinic

Contact Dermatitis | June 18, 2022 | Volume: 87 | Issue: 4 | Pages: 385-386

10.1111/cod.14175 | PMID 35715879 Get It

Stable Leukoencephalopathy in a Patient With ACTA2 -Associated Multisystem Smooth Muscle Disorder
Bieber, David, Renaud, Deborah L. , Bieber, David, Port, John D.

Mayo Clinic

Neurology | June 17, 2022 | Volume: 99 | Issue: 8 | Pages: 338-340

10.1212/wnl.0000000000200961 | PMID 35715202 Get It

Action for Increasing Diversity, Market Access, and Capacity in Oncology Registration Trials—Is Africa the Answer? Report From a Satellite Session of the Accelerating Anti-Cancer Agent Development and Validation Workshop
Kizub, Darya , Manner, Cathyryne K. , Graef, Katy, Abubakar, Bello , Orem, Jackson , Odedina, Folakemi T. , Adeyeye, Mojisola Christianah, Nakigudde, Gertrude , Ayalew, Kassa , Kalidas, Chitkala , Lyerly, H. Kim , Norman, Thea , Freedman, Jamie, Dent, Jennifer , Cance, Bill, Bello, Abubakar Mohammed , Odedina, Folakemi , Dent, Jennifer , Cance, Bill , Gralow, Julie R , Fashoyin-Aje, Lola , Gralow, Julie R.

Mayo Clinic

JCO Global Oncology | June 17, 2022 | Volume: No volume available | Issue: 8 | Pages: No page available

10.1200/go.22.00117 | PMID 35714309 Get It

Patients of African ancestry are not well-represented in cancer clinical trials despite bearing a disproportionate share of mortality both in United States and Africa. We describe key stakeholder perspectives and priorities related to bringing early-stage cancer clinical trials to Africa and outline essential action steps. Increasing Diversity, Market Access, and Capacity in Oncology Registration Trials—Is Africa the Answer? satellite session was organized at 2021 Accelerating Anti-Cancer Agent Development and Validation Workshop. Panelists included representatives of African Organization for Research and Training in Cancer, Uganda Cancer Institute, Uganda Women's Cancer Support Organization, BIO Ventures for Global Health, Bill & Melinda Gates Foundation, the US Food and Drug Administration, Nigeria's National Agency for Food and Drug Administration and Control, Bayer, and Genentech, with moderators from ASCO and American Cancer Society. Key discussion themes and resulting action steps were agreed upon by all participants. Panelists agreed that increasing diversity in cancer clinical trials by including African patients is key to ensuring novel drugs are safe and effective across populations. They underscored the importance of equity in clinical trial access for patients in Africa. Panelists discussed their values related to access and barriers to opening clinical trials in Africa and described innovative solutions from their work aimed at overcoming these obstacles. Multisectoral collaboration efforts that allow leveraging of limited resources and result in sustainable capacity building and mutually beneficial long-term partnerships were discussed as key to outlined action steps. The panel discussion resulted in valuable insights about key stakeholder values and priorities related to bringing early-stage clinical trials to Africa, as well as specific actions for each stakeholder group.
Burnout and well‐being in otolaryngology trainees: A systematic review
Lawlor, Skye K., Carlson, Matthew L. , Rajasekaran, Karthik , Low, Christopher M. , Rajasekaran, Karthik , Choby, Garret

Mayo Clinic

World Journal of Otorhinolaryngology - Head and Neck Surgery | June 17, 2022 | Volume: 8 | Issue: 2 | Pages: 118-125

10.1002/wjo2.21 | PMID 35782400 Get It

AbstractObjectiveTo comprehensively review the recent published literature to characterize current trends of burnout and well‐being among otolaryngology trainees.MethodsStudy design: systematic review and meta‐analysis. A comprehensive literature review from 2000 to 2021 of studies related to otolaryngology resident burnout and well‐being, as well as the general topic of well‐being among surgical residents was completed. All included studies were summarized qualitatively. For the quantitative analysis, only articles reporting a Maslach burnout inventory (MBI), modified MBI or Mini‐Z‐ Burnout assessment were included.ResultsTwenty‐five articles were included in the qualitative summary and nine articles in the quantitative analysis. In the qualitative summary, trainees were reported to have increased levels of distress and emotional hardening compared to attending otolaryngologists. Total hours worked per week and female gender were associated with worsened well‐being. Residency program strategies to improve trainee well‐being include program‐sponsored wellness activities, dedicated wellness champions, and assistance with clerical burden. Implementation of protected nonclinical time has been shown to decrease burnout and increase well‐being among trainees. Moreover, formal trainee mentorship programs have also been shown to reduce trainee burnout and stress. In the quantitative analysis, rates of trainee burnout ranged from 29.7% to 86% with an overall trend towards reduced rates of burnout from 2006 to 2021. Utilizing a weighted average, the overall burnout among otolaryngology residents was 58.6%.ConclusionsRates of burnout remain high among otolaryngology trainees. Implementing formal mentorship programs and providing protected time during regular work hours appear to be effective tools to improve resident well‐being.
Editorial Commentary on A Call to Action: The Case for Surgical Log Credit for International Rotations and Further Action by the Academic Urology Leadership
Husmann, Douglas A.

Mayo Clinic

Urology Practice | June 17, 2022 | Volume: 9 | Issue: 4 | Pages: 275-276

10.1097/upj.0000000000000319 | PMID 37145796 Get It

NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022
Wierda, William G. , Brown, Jennifer R. , Bilgrami, S, Bociek, Greg, Brander, Danielle M. , Chanan‐Khan, Asher , Davis, Randall S. , Eradat, Herbert, Fletcher, Christopher D.�M. , Gaballa, Sameh , Hamid, Muhammad Saad , Hernandez‐Ilizaliturri, Francisco J. , Hill, Brian T. , Kaesberg, Paul, Kaplan, Lawrence D. , Ma, Shuo , Mato, Anthony, Mosse, Claudio A. , Stephens, Deborah M. , Ujjani, Chaitra S. , Wagner‐Johnston, Nina D. , Woyach, Jennifer A. , Ye, J Christine, Dwyer, Mary A., Sundar, Hema, Chanan-Khan, Asher A., Stephens, Deborah M , Ma, Shuo , Wierda, William G. , Abramson, Jeremy S. , Awan, Farrukh T. , Coutré, Steven , Ghobadi, Armin , Kamdar, Manali , Khan, Nadia , Kipps, Thomas J. , Schuster, Stephen J. , Siddiqi, Tanya

Mayo Clinic

Journal of the National Comprehensive Cancer Network | June 17, 2022 | Volume: 20 | Issue: 6 | Pages: 622-634

10.6004/jnccn.2022.0031 | PMID 35714675 Get It

The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton’s tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors has emerged as an effective chemotherapy-free option for patients with previously untreated or relapsed/refractory CLL/SLL. Undetectable minimal residual disease after the end of treatment is emerging as an important predictor of progression-free and overall survival for patients treated with fixed-duration BCL-2 inhibitor-based treatment. These NCCN Guidelines Insights discuss the updates to the NCCN Guidelines for CLL/SLL specific to the use of chemotherapy-free treatment options for patients with treatment-naïve and relapsed/refractory disease.
It is beneficial to invest resources to implement proton intracranial SRS
Deraniyagala, Rohan, Ding, Xuanfeng , Alonso‐Basanta, Michelle , Li, Taoran , Rong, Yi

Mayo Clinic

Journal of Applied Clinical Medical Physics | June 17, 2022 | Volume: 23 | Issue: 7 | Pages: No page available

10.1002/acm2.13701 | PMID 35713887 Get It

Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Gradishar, William J. , Moran, Meena S. , Abraham, Jame , Aft, Rebecca , Allison, Kimberly H. , Anderson, Bethany , Burstein, Harold J. , Chew, Helen K. , Dang, Chau T. , Goldstein, Lori J. , Hurvitz, Sara A. , Isakoff, Steven J. , Jankowitz, Rachel C. , Javid, Sara H. , Leitch, Marilyn , Lyons, Janice A., Patel, Sameer A. , Pierce, Lori J. , Rosenberger, Laura H. , Sitapati, Amy M. , Smith, Mary Lou , Stringer-Reasor, Erica , Telli, Melinda L. , Wisinski, Kari B. , Burns, Jennifer L. , Telli, Melinda L , Agnese, Doreen Marie , Elias, Anthony , Giordano, Sharon H. , Goetz, Matthew P. , Krishnamurthy, Jairam , Mortimer, Joanne , Rugo, Hope S. , Smith, Karen L. , Soliman, Hatem Hussein , Ward, John Headley , Young, Jessica S. , Kumar, Rashmi

Mayo Clinic

Journal of the National Comprehensive Cancer Network | June 17, 2022 | Volume: 20 | Issue: 6 | Pages: 691-722

10.6004/jnccn.2022.0030 | PMID 35714673 Get It

The therapeutic options for patients with noninvasive or invasive breast cancer are complex and varied. These NCCN Clinical Practice Guidelines for Breast Cancer include recommendations for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget disease, phyllodes tumor, inflammatory breast cancer, and management of breast cancer during pregnancy. The content featured in this issue focuses on the recommendations for overall management of ductal carcinoma in situ and the workup and locoregional management of early stage invasive breast cancer. For the full version of the NCCN Guidelines for Breast Cancer, visit NCCN.org .